澳门·威尼克斯人(Venetian)官方网站-The Venetian Macao

Ribo's International R&D Center Ribocure Closes USD 33 Million Equity Financing to Accelerate Innovative siRNA Drug Development

Ribo's International R&D Center Ribocure Closes USD 33 Million Equity Financing to Accelerate Innovative siRNA Drug Development

Ribo Announces siRNA-based Treatment of Autoimmune Diseases (RBD2080) Received Clinical Approval in Australia

Ribo Announces siRNA-based Treatment of Autoimmune Diseases (RBD2080) Received Clinical Approval in Australia

First Milestone Successfully Achieved in Ribo’s Collaboration in Liver Diseases With Boehringer Ingelheim

First Milestone Successfully Achieved in Ribo’s Collaboration in Liver Diseases With Boehringer Ingelheim

Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeutics

Ribo Presents First-In-Class FXI Targeting siRNA Drug RBD4059 Phase Ⅰ Clinical Data At ESC Congress 2024

Ribo Presents First-In-Class FXI Targeting siRNA Drug RBD4059 Phase Ⅰ Clinical Data At ESC Congress 2024